Clinical trials: Patient With Colorectal Cancer
Chemotherapy Induced Peripheral Neuropathy
The Possible Protective Role of Omeprazole Against Oxaliplatin Induced Neuropathy in Cancer Patients
Oxaliplatin(OXA) chemotherapy protocols are used in treatment of cancers like colorectal (CRC) and pancreatic cancer. OXA causes peripheral neuropathy which is considered treatment limiting factor.
- Trial name
- NCT05680870
- Testing
- Omeprazole
- Where
- Egypt
- Volunteers
- 46 people
- Sponsor
- Aya Mohamed Sadek Elsaid
Solid Tumor
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
This is a first in human, single arm, open label, Phase 1a/1b study to determine the safety, feasibility, and efficacy of a single dose of NeoTCR-P1 T cells in participants with solid tumors.
- Trial name
- NCT03970382
- Testing
- NeoTCR-P1 adoptive cell therapy, nivolumab, IL-2
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- PACT Pharma, Inc.
Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8, Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8
Real-Time Monitoring of Chemotherapy Side-Effects in Patients With Gastrointestinal Cancers, RT-CAMSS Study
This trial tests new methods and materials for the real-time chemotherapy-associated side effects monitoring support system (RT-CAMSS) in patients with gastrointestinal cancers undergoing chemotherapy.
- Conditions
- Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8, Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage 0 Gastric Cancer AJCC v8, Clinical Stage I Esophageal Adenocarcinoma AJCC v8
- Trial name
- NCT04449679
- Testing
- Patient Monitoring System, Questionnaire Administration, Consultation
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Thomas Jefferson University
Colorectal Cancer, Metastasis
PET-CT and Circulating Tumor Cells in Colorectal Cancer
The purpose of this study is to identify an early indicator of drug efficacy in patients with advanced colorectal cancer - a prospective evaluation of circulating tumor cells, positron-emission tomography scan and RECIST criteria.
- Trial name
- NCT01163305
- Testing
- Chemotherapy
- Where
- Hong Kong
- Volunteers
- 84 people
- Sponsor
- Chinese University of Hong Kong
Metastatic Colorectal Cancer
Image Guided Treatment Optimization With Cetuximab for Patients With Metastatic Colorectal Cancer
In this study the investigators will evaluate the uptake of 89Zirconium labeled cetuximab in extra-hepatic colorectal metastases. The investigators hypothesize that uptake of 89Zr-cetuximab is required for response to cetuximab.
- Trial name
- IMPACT-CRC (NCT02117466)
- Testing
- Dose escalation cetuximab, Standard dose cetuximab
- Where
- 3 sites in Netherlands
- Volunteers
- 85 people
- Sponsor
- Amsterdam UMC, location VUmc
Colorectal Cancer (Locally Advanced or Metastatic)
A Study to Assess Safety and Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal Cancer
SOT109 is a special cancer medicine designed to find and kill certain cancer cells that carry a marker called CDH17, while causing less harm to healthy cells. The study consists of two parts, Part A and Part B.
- Trial name
- NCT07693751
- Testing
- SOT109
- Where
- 3 sites in United States, Moldova
- Volunteers
- 100 people
- Sponsor
- SOTIO Biotech a.s.
Metastatic Colorectal Cancer
A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer
This is an open-label, multicenter, phase 1 study of BBI608 in combination with FOLFIRI + Bavacizumab. This study population is adult Japanese patients with metastatic colorectal cancers in FOLFIRI + Bevacizumab combination…
- Trial name
- NCT02641873
- Testing
- BBI608, 5-FU, Irinotecan
- Where
- 2 sites in Japan
- Volunteers
- 4 people
- Sponsor
- Sumitomo Pharma Co., Ltd.
Colorectal Cancer, High Grade Serous Ovarian Cancer
A Phase I Trial of LY3143921 Hydrate in Solid Tumours
This clinical study looked at a drug called LY3143921 hydrate (a Cdc7 inhibitor) in adult patients with advanced solid tumours. The main aims were to find out the maximum dose of LY3143921 hydrate that could be given safely to…
- Conditions
- Colorectal Cancer, High Grade Serous Ovarian Cancer, Non Small-cell Lung Cancer (Squamous Cell Variant), Urothelial Cancer
- Trial name
- NCT03096054
- Testing
- LY3143921 hydrate
- Where
- 4 sites in United Kingdom
- Volunteers
- 69 people
- Sponsor
- Cancer Research UK
Advanced Colorectal Cancer
Folfiri/aflIbercept in Metastatic coloreCTal Cancer patIents With RAS Validated Wild typE Status
The study will a be a biologically enriched, prospectively stratified phase II trial in RAS wild type metastatic colorectal cancer patients progressing after first-line treatment with oxaliplatin, fluoropyrimidines and an…
- Trial name
- DISTINCTIVE (NCT04252456)
- Testing
- Aflibercept, 5fluorouracil, Folinic Acid andIrinotecan
- Where
- 16 sites in Italy
- Volunteers
- 150 people
- Sponsor
- Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Colorectal Carcinomatosis
Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis French Part of the Main Bev-IP Study
Selected patients with peritoneal carcinomatosis (PC) from colorectal cancer (CRC) benefit from cytoreductive surgery (CRS) combined with intraperitoneal chemoperfusion (IPC).
- Trial name
- NCT03161041
- Testing
- Cytoreductive surgery combined with HIPEC, bevacizumab and HIPEC (Oxaliplatin 360 mg/m2).
- Sponsor
- Hospices Civils de Lyon
Metastatic Colorectal Cancer
QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer
The purpose of this study is to evaluate the efficacy and safety of QL1706 Injection in combination with bevacizumab and XELOX compared with placebo in combination with bevacizumab and XELOX for first-line treatment in patients…
- Trial name
- NCT07025239
- Testing
- QL1706, Bevacizumab, Oxaliplatin
- Volunteers
- 430 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Rectal Cancer
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer
This is a multicenter, prospective, randomized, stratified, controlled, open-label study comparing preoperative FOLFOX versus postoperative risk-adapted chemotherapy in patients with locally advanced rectal cancer and low risk…
- Trial name
- NCT04495088
- Testing
- mFOLFOX (neoadjuvant), XELOX (neoadjuvant), mFOLFOX (adjuvant)
- Where
- Germany
- Volunteers
- 215 people
- Sponsor
- Ralf Hofheinz
Colorectal Cancer
Olimersen and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Gene therapy such as oblimersen may make tumor cells more sensitive to chemotherapy drugs.
- Trial name
- NCT00004870
- Testing
- oblimersen sodium, irinotecan hydrochloride
- Where
- 3 sites in United States
- Sponsor
- The University of Texas Health Science Center at San Antonio
Metastatic Colorectal Cancer
Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases
The goal of this clinical trial is to evaluate the superiority of ivonescimab combined with FOLFIRI over FOLFIRI + bevacizumab as second-line treatment of non resectable pMMR/MSS BRAFwt mCRC patients without liver metastases in…
- Trial name
- COLIBRI-GI (NCT07359456)
- Testing
- Ivonescimab, Bevacizumab, FOLFIRI Protocol
- Where
- 22 sites in France
- Volunteers
- 130 people
- Sponsor
- UNICANCER
Colorectal Cancer
Default Genetics Referrals for Young-Onset Colorectal Cancer
The investigators will perform a pilot implementation study of a default genetics referral process among patients with young-onset CRC diagnosed between ages 40 and 49.
- Trial name
- NCT05018156
- Testing
- Default Genetics Referral Process
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- University of Pennsylvania
Familial Adenomatous Polyposis
Niclosamide for Familial Adenomatous Polyposis
Familial adenomatous polyposis (FAP) leads to adenomas and eventual adenocarcinomas in colon and less frequently, duodenum. Chemopreventive strategies have been studied in FAP patients to delay the development of adenomas and…
- Trial name
- NCT04296851
- Testing
- Niclosamide
- Where
- South Korea
- Volunteers
- 72 people
- Sponsor
- Yonsei University
Colorectal Carcinoma
IMA910 Plus GM-CSF With Low-dose Cyclophosphamide Pre-treatment in Advanced Colorectal Carcinoma Patients Following a Successful 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy (IMA910-101)
This study is being conducted in order determine whether IMA910 as single agent with GM-CSF as adjuvant following pre-treatment with low-dose cyclophosphamide is safe and shows sufficient anti-tumour effectiveness in patients…
- Trial name
- IMA910-101 (NCT00785122)
- Testing
- Endoxana, Leukine, IMA910, Endoxana, Leukine, IMA910, Aldara
- Where
- 41 sites in Belgium, Bulgaria and 7 more
- Volunteers
- 92 people
- Sponsor
- Immatics Biotechnologies GmbH
Colorectal Neoplasms
Prognostic Value of Circulating Tumoral Free DNA Versus Circulating Tumoral Cells in Patients With Colorectal Cancer Stage II-III
After curative surgical resection, detection of metastatic lymph node remains the main prognostic validated criteria on which is based the decision of adjuvant therapy.
- Trial name
- CTC (NCT02556281)
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 216 people
- Sponsor
- University Hospital, Rouen
Colorectal Cancer
Molecular Determinants of Response to Preoperative Therapy in Patients With Locally Advanced Colorectal Cancer
The goal of this laboratory research is to look for genes that can predict which patients will achieve a complete disappearance of their colorectal cancer after treatment like chemotherapy, radiation, or other therapy.
- Trial name
- NCT02877056
- Testing
- Endoscopy
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Colorectal Cancer
A Retrospective Review of Liver Resection Rate in Metastatic Colorectal Cancer Patients Following Downsizing Treatment With Chemotherapy Plus Cetuximab in Normal UK National Health Service Clinical Practice
This study is a multi-centre retrospective observational research study which will be conducted in UK centres with specialised liver surgical services.
- Trial name
- RESECT (NCT01460745)
- Where
- 5 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.